Terms: = Kidney tumors AND HNRNPA2B1, ENSG00000122566, SNRPB1, RNPA2, HNRPB1, HNRPA2, HNRNPB1, HNRNPA2, 3181
10 results:
1. LINC00645 inhibits renal cell carcinoma progression by interacting with hnrnpa2b1 to regulate the ROCK1 mRNA stability.
Li H; Han X; Song L; Li X; Zhang L; Jin Z; Zhang Y; Wang T; Huang Z; Jia Z; Yang J
Gene; 2024 May; 905():148232. PubMed ID: 38309317
[TBL] [Abstract] [Full Text] [Related]
2. Extracellular vesicle-circEHD2 promotes the progression of renal cell carcinoma by activating cancer-associated fibroblasts.
He T; Zhang Q; Xu P; Tao W; Lin F; Liu R; Li M; Duan X; Cai C; Gu D; Zeng G; Liu Y
Mol Cancer; 2023 Jul; 22(1):117. PubMed ID: 37481520
[TBL] [Abstract] [Full Text] [Related]
3. N
von Hagen F; Gundert L; Strick A; Klümper N; Schmidt D; Kristiansen G; Tolkach Y; Toma M; Ritter M; Ellinger J
Mol Carcinog; 2021 May; 60(5):354-362. PubMed ID: 33755994
[TBL] [Abstract] [Full Text] [Related]
4. Identification of a New Prognostic Risk Signature of Clear Cell Renal Cell Carcinoma Based on N
Zhang Y; Yao Y; Qi X; Li J; Liu M; Che X; Xu Y; Wu G
J Immunol Res; 2021; 2021():6617841. PubMed ID: 33628845
[TBL] [Abstract] [Full Text] [Related]
5. Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential.
Li H; Liu J; Shen S; Dai D; Cheng S; Dong X; Sun L; Guo X
J Cell Mol Med; 2020 Oct; 24(19):11111-11119. PubMed ID: 32915499
[TBL] [Abstract] [Full Text] [Related]
6. Identification of anti-tumoral feedback loop between VHLα and hnrnpa2b1 in renal cancer.
Liu Y; Zhang H; Li X; Zhang C; Huang H
Cell Death Dis; 2020 Aug; 11(8):688. PubMed ID: 32826868
[TBL] [Abstract] [Full Text] [Related]
7. Altered expression of the clock gene machinery in kidney cancer patients.
Mazzoccoli G; Piepoli A; Carella M; Panza A; Pazienza V; Benegiamo G; Palumbo O; Ranieri E
Biomed Pharmacother; 2012 Apr; 66(3):175-9. PubMed ID: 22436651
[TBL] [Abstract] [Full Text] [Related]
8. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract] [Full Text] [Related]
9. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
[TBL] [Abstract] [Full Text] [Related]
10. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function.
Carles J; Nogué M; Domènech M; Pérez C; Saigí E; Villadiego K; Guasch I; Ibeas R
Oncology; 2000 Jun; 59(1):24-7. PubMed ID: 10895062
[TBL] [Abstract] [Full Text] [Related]
